OBR Daily Commentary

forumImage

Cancer's Big Infrastructure Problem

(Forbes) June 15, 2017 - We need to do more than just raise cancer drug prices yet again. We need to invest in the kind of infrastructure that will make it possible to test many of these medicines, and speed up innovation further.

Read Article arrow

Winston Wong, PharmD (Posted: June 16, 2017)

quotesThere is an infrastructure problem, and the problem is that we need to do a better job to show the trust value of the generic profiling so that it will be paid for. If the tests are covered, the drugs will be used. Next, we need to have more comparative trials between like drug in classes so we definitely will know if one drug is better over another. Finally, we need to rebuild the entire reimbursement system so that pricing is not driven by what the market will accept. Simple changes .... Let's get them done!!quotes

Reply

Thomas Marsland, MD (Posted: June 16, 2017)

quotesSo right patient, right drug, right time. But it is not really that easy. As the author suggest more research is needed but in these tumors with rare targetable mutations collecting enough data is difficult. The prospective randomize trial will always be the gold standard but for rare tumors we may well have to rely on pooled real world data. Agree that the infrastructure is not yet in place but a number of programs such as ASCO's Cancer LinQ are being developed. It is critical that all of us participate in this and like programs to assure that we can accumulate sufficient data to help decide who is the right patient; which is the right drug; and when is the right time.quotes

Reply

Add Comment 2 Comment(s)

Meet the Editorial Board

Community Oncology
member photo
Dean Gesme, MD

FACP FACPE FASCO President, Minnesota Oncology...

Breast Cancer
member photo
Debu Tripathy, MD

Professor and Chair, Department of Breast Medical Oncol...

Lung Cancer
member photo
H. Jack West, MD

Medical Director, Thoracic Oncology Program, Swedish Ca...

Gastrointestinal Cancers
member photo
Howard S. Hochster, MD

Associate Cancer Center Director, Yale Cancer Center P...

Community Oncology
member photo
Jeff Patton, M.D.

CEO Tennessee Oncology...

Precision Medicine Section Editor
member photo
Jennifer Levin Carter, MD, MPH

Chief Medical Officer and Founder, N-of-One...

Financial Sector
member photo
Michael G. King Jr.

Managing Director and Senior Biotechnology Analyst...

Gastrointestinal Cancers
member photo
Richard Goldberg, MD

Director WVU Cancer Institute Director of Cancer Signa...

Editor-In-Chief
member photo
Robert A. Figlin, MD., FACP

Professor and Director, Division of Hematology Oncology...

Health Policy
member photo
Ted Okon

Executive Director Community Oncology Alliance...

Community Oncology
member photo
Thomas Marsland, MD

Vice President Integrated Community Oncology Network ...

Community Oncology
member photo
William Harwin MD

Florida Cancer Specialists President and Managing Part...

Health Policy
member photo
William McGivney, PhD

National Health Policy Expert...

Payer
member photo
Winston Wong, PharmD

President, W-Squared Group...